The total treatment costs ranged from EUR 6,631 for the voriconazole/caspofungin strategy to EUR 17,742 for the L-AMB/voriconazole plus caspofungin strategy.
The LYGs ranged from 1,109 for the L-AMB/caspofungin strategy to 1,307 for the voriconazole/L-AMB plus caspofungin strategy.
All strategies but the voriconazole/L-AMB plus caspofungin were dominated by the voriconazole/caspofungin strategy as this was less costly and more effective.
Voriconazole/L-AMB plus caspofungin was more effective compared with voriconazole/caspofungin, resulting in an incremental cost-effectiveness ratio (ICER) of EUR 107,036 per incremental LYG.
The one-way sensitivity analyses showed that the results were most sensitive to variations in the number of vials of L-AMB per day, and the number of days of other licensed antifungal therapy (OLAT) treatment. The cost-effectiveness acceptability curves demonstrated that, at various values of willingness-to-pay, the voriconazole/caspofungin strategy mostly produced the highest net monetary benefit.